使用单层系统从诱导多能干细胞体外分化人CD45 CD34诱导造血祖细胞。

In vitro differentiation of human CD45 CD34 induced hematopoietic progenitor cells from iPSCs using a monolayer system.

作者信息

Liu Zhongfeng, Liu Weihua, Chen Zhiguo, Kang Hua

机构信息

Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing 100069, China; Department of General Surgery, Center for Thyroid and Breast Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing 100069, China; Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen 518055, China.

出版信息

Transfus Apher Sci. 2024 Feb;63(1):103866. doi: 10.1016/j.transci.2023.103866. Epub 2023 Dec 20.

DOI:10.1016/j.transci.2023.103866

PMID:38182435

Abstract

Hematopoietic stem cells (HSCs) represent crucial target cells in the management of hematopoietic and immune system disorders. Unfortunately, the primary source of hematopoietic stem cells is limited. Hematopoietic stem cells derived from induced pluripotent stem cells (iPSCs) hold great promise for applications in cell therapy, disease modeling, and drug screening. To achieve a consistent induction method, one specific induction scheme capable of reliably generating CD34 and CD45 double-positive cells from iPSCs was optimized, employing a comparative analysis and screening of various induction methods. The comprehensive induction procedures are outlined in this document.

摘要

造血干细胞（HSCs）是治疗造血和免疫系统疾病的关键靶细胞。不幸的是，造血干细胞的主要来源有限。诱导多能干细胞（iPSCs）来源的造血干细胞在细胞治疗、疾病建模和药物筛选方面具有广阔的应用前景。为了实现一种一致的诱导方法，通过对各种诱导方法进行比较分析和筛选，优化了一种能够可靠地从iPSCs产生CD34和CD45双阳性细胞的特定诱导方案。本文件概述了全面的诱导程序。